We tested the hypothesis that some cereal-product vehicles may reduce fortificant bioavailability below 85% and examined the feasibility of using single dose, dual-label, non-saturation protocols for studying bioavailability based on urinary excretion ratios (UER; % oral 13 C 6 isotope dose excreted in intact folate/% IV 2 H 4 isotope dose excreted). Fifteen females received 225 µg oral folate (capsules, fortified bran flakes, and fortified white bread), mainly as 13 C 6 -PteGlu, followed by IV injection of 100 µg 2 H 4 -PteGlu. UERs were used as the primary index of absorption. Urinary folate was cleaved to p-aminobenzoylglutamic acid, dervivatized and determined by gas chromatography/mass spectroscopy (GC/MS). The UER mean (95%CI) for folic acid was 2.18 (1.2-3.8) at 48 hours and as these were greater than 1.0, it was concluded that oral and IV isotopes of folic acid are handled differently by the body. Compared to the 48 hour UER for folic acid, UERs for white bread and bran flakes were 0.71 and 0.37, respectively, thus indicating some matrix inhibition of absorption. Consideration should be given to the choice of cereal-based fortification vehicles in order to maximize bioavailability. Plasma enrichment of folate can be measured using LC/MSMS (liquid chromatography/mass spectroscopy-mass spectroscopy) but seems unfeasible with the GC/MS method.
Introduction
Folates are crucial for nucleotide synthesis, cell division, and gene expression [1] . Periconceptual supplementation of women with folic acid has been shown to significantly reduce the incidence and reoccurrence of neural tube defects, such as spina bifida [2, 3] . Marginal folate deficiency is also associated with elevated plasma homocysteine, an emerging risk factor for vascular diseases and stroke [4, 5] , linked to some cancers [6, 7] and age-related cognitive decline [8] . Folate fortification of cereal-based foods with folic acid at a concentration of 140 µg/100g has been mandatory in the United States since 1998 [9] , and it is currently under review in the United Kingdom and other European countries.
Although humans absorb folic acid well in the absence of food, little is known about its absorption from fortified foods. Published studies have provided conflicting results, with absorption values of PteGlu (pterolymonoglutamic acid) from fortified foods ranging from 30% to 90%, and the food matrix having considerable, small, or no effect on the amount absorbed. This variation may be due to methodological factors, such as the very limited short-term plasma response which is generally thought to make plasma kinetics of limited usefulness in assessing the relative bioavailability of nutritionally relevant oral doses of folate, the influence of pre-study folate-saturation, the use of large, less nutritionally relevant, oral test doses, and the potential for incomplete retention of folate during preparation of food test products.
Isotopic methods permit the examination of folate absorption and metabolism with a high degree of specificity and sensitivity [10] . These methods are based on a single-dose dual-label approach in which two isotopically labeled forms of folic acid [ 13 C and 2 H] are administered; one as an oral [ 13 C] and one as an intravenous [ 2 H] dose. Urinary excretion (24 hours) of both isotopes, in isolated intact folate, are measured and the percentage of the oral and IV doses excreted calculated, and then expressed as the urinary excretion ratio (UER).
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The purpose of this study was threefold. First, to critically evaluate the dual-label method in a human study, with no folate pre-saturation, and where postdose urine was collected long enough (48 hours) to encompass two potentially differing pulses in excretion of isotope-labeled folate. Second, the dual oral/IV method was evaluated in the context of studying potential matrix effects on the bioavailability of folic acid from two fortified cereal-based foods.Third, the advantages of using a direct LC-MS/MS procedure for the determination of isotopically labeled folates in biological samples were compared to the current gas chromatography/mass spectroscopy (GC/MS) procedure. 
Methods and materials
]-L-glutamic acid using a previously developed method [11] . Singly-labeled [ 13 C 6 ]-and [ 2 H 4 ]-p-aminobenzoyl-L-glutamate (PABG) was prepared for use as calibrants, and doubly-labeled [ 13 C 6 , 2 H 4 ]-PABG was prepared as an internal standard (isotopic enrichments were 96%, 90%, and 82%, respectively).
Gelatin capsules, containing 13 C 6 -PteGlu in a stable formulation, were manufactured to GMP standards by RP Scherer Ltd, Swindon, UK. The contents of 20 capsules were assayed for PteGlu, using a high performance liquid chromatography (HPLC) procedure with ultra violet detection [12] , and found to contain 56.0 µg per capsule. Capsules were stored in the dark at +4°C. The folate content was checked every six months and found to be stable for the period of study. Solutions of 2 H 4 -PteGlu for intravenous (IV) injection were prepared using a previously published procedure [13] by the Pharmacy Manufacturing Unit, Ipswich NHS Hospital Trust, Ipswich, UK. Ten percent of ampoules were selected for virulence testing, and the remainder stored frozen at -18°C. The mean concentration of PteGlu in 5 vials, as determined by HPLC [12] , was 87.2 µg/ml. Two fortified foods were prepared commercially containing 13 C 6 PteGlu: a breakfast cereal (bran flakes) and a white sliced bread as reported elsewhere [12] . Homogeneity of added folic acid to the bran flakes and white bread was checked by measuring total folate by microbiological assay using hog kidney deconjugase and α-amylase [14] . The mean (±SEM) concentration of folate in fortified and unfortified bran flakes was 248 (10.4 µg/100g) and 33 µg/100g, respectively, indicating that 13% of the total folate present in the fortified bran flakes was of natural origin. The mean (±SEM) concentration of folate in fortified and unfortified white bread was 191 (6.6 µg/100g) and 21 µg/100g, respectively, indicating that 11% of the total folate present in the fortified bran flakes was of natural origin.
Experimental design and study volunteers
The study was approved by the Norwich and District Ethics Committee (Norfolk and Norwich Area Health Care Trust). Fifteen healthy women volunteers (aged 19 to 43 years) were recruited from the staff and the local population. An initial fasting blood sample was taken from all volunteers to check for normal blood biochemistry, serum B 12 , plasma and erythrocyte folate, and total homocysteine concentrations. After giving written consent, each volunteer participated for three test days (folic acid capsules, fortified white bread, and fortified bran flakes), which were scheduled at least three weeks apart to minimize the risk of isotope carry-over between doses. Each volunteer received the treatments in a random cross-over fashion. The volunteers were asked to avoid excessive consumption of folate-rich or fortified foods (a list was provided) for three days prior to and subsequent to each of the test days. For the remainder of the study they ate and recorded (weighed-record) their usual diet. For each test day, following an overnight fast, volunteers received an oral dose of folate in the form of either four gelatin capsules containing 13 C 6 -PteGlu (224 µg total), 91g fortified bran flakes containing a total of 225 µg folate (196 µg 13 C 6 -PteGlu and 29 µg folate of natural origin) or 118g white sliced bread containing a total of 225 µg folate (200 µg 13 C 6 -PteGlu and 25 µg folate of natural origin). All doses were digested within 15 minutes, with the aid of water only, and an intravenous injection of 100 µg 2 H 4 -PteGlu in saline was administered 15 minutes after the start of consumption. Volunteers were given a light, low-folate, lunch four hours after the oral dose. Three 24-hour urine samples were collected from each volunteer (24 hour period prior to treatment, 0 to 24 hour period post-treatment and 24-48 hours period post-treatment).
Habitual dietary intake data was obtained using written, weighed, records completed every sixth day for seven weeks during the study period, excluding test days and the three days before and after, when volunteers were asked to avoid excessive consumption of folate-rich or fortified foods. Dietary records were coded [15] and mean daily nutrient intakes calculated.
Methods
Red-cell folate and serum B 12 were measured by chemiluminescent immunoassay (Beckman Access, Beckman-Coulter, Ltd. High Wycombe, UK) and enzyme immunoassay (Abbott Laboratories, Maidenhead, UK), respectively, at a local hospital, and total plasma L-homocysteine by fluorescence polarization immunoassy (IMx System, Abbott Laboratories; [16] . A modification of a previously published GC/MS procedure was used to determine total labeled urinary folate [17] . Full details for sample preparation and determination are given elsewhere [12] . The method comprises of extraction and isolation of intact folate from urine, chemical cleavage of the C-9/N-10 bond to PABG, isolation of para-amino benzoyl glutamate (PABG) by HPLC, derivatization of PABG and GC/MS of the resulting lactam ( fig. 1 ). The excretion of each isotopomer (M0, M4, and M6 derivatized PABG fractions) in intact urinary folate was calculated from the total daily urine volume and the ratios M0/M4 and M0/M6. To facilitate comparisons between test-days, excretion data were calculated as urinary excretion ratios (UERs).
Volunteers acted as their own controls. Data for the percentage dose of each isotopomer excreted into the urine in intact folate, and urinary excretion ratios (UER), were mathematically-transformed (log 10 ) to normalize distributions. The results were then examined 'within-subject' using 1-way analysis of variance (1-AOV) and least significant difference (LSD) tests for planned comparisons.
Results and discussion
All volunteers had normal hematological and plasma glucose, and lipid status (table 1). Folate status (plasma and erythrocyte folate concentrations), total plasma homocysteine and average folate intakes were well within accepted normal ranges. Total urinary excretion of both isotopes in intact folate by 48 hours post-dose (expressed as % of initial oral or IV dose), for the three treatments are given in table 2, together with calculated urinary excretion ratios (UERs).
Pre-saturation versus non-saturation protocols
The mean urinary recovery of total labeled folates was found to be 0.3% to 1.3% of the administered dose during the 48-hour post-dose period. This excretion pattern corresponds favorably to other published data using a dual-label stable isotope protocol in which 0.1% to 0.5% of the administered dose was found during a 36-hour post-dose period [18] . The recovery of intact labeled folate in urine is much higher (typically 10% to 30% of the dose) when single dose administration of stable isotope labeled folates follows pre-dose satu- ration with folic acid [18] . However, the use of folate saturation is considered to be non-physiologic with different in vivo folate kinetics compared to the nonsaturation protocols used here. Complete recovery of the isotopically labeled dose as intact urinary folate is not expected because of in vivo retention, catabolism, and fecal excretion. The low enrichments in urine, along with low rates of folate excretion, contribute to large between-subject variations but this variability is offset by the use of the urinary excretion ratio as the primary indicator of bioavailability. Increasing the urinary excretion of the label might be possible by using larger oral doses, or by multiple-doses over several days, and this could be used to improve between-subject variability. However, once doses exceed 400µg, the possibility that unmetabolized folic acid appearing in the plasma must be taken into account.
Handling of oral and IV isotopes by the body
Provided doses are not excessive (< 400µg/dose), oral folic acid absorbed by enterocytes will be reduced and methylated prior to transfer into the body proper where it will appear in the circulation as [ 13 C 6 ]-5-CH 3 H 4 PteGlu. In the dual-label stable isotope protocol it is assumed that the in vivo kinetics, distribution, and excretion of both the oral [ 13 C]folate, and IV [ 2 H]folate are equivalent and independent of the mode of administration. If absorption of the oral dose was100%, then a UER which does not depart significantly from unity would be expected.
Of the total dose of isotope excreted over the 48-hour period, the proportion of the oral 13 C 6 dose excreted in the first 24 hours for capsules, white bread, and bran flakes was 0.90, 0.95, and 0.77, respectively. These were significantly greater than the comparative proportions of IV 2 H 4 dose excreted in the first 24 hours, which were 0.53, 0.69, and 0.62, respectively. As indicated by 1-AOV 'within-subject,' there was no significant difference in the proportion of the IV 2 H 4 dose excreted by 48 hours for capsules, white bread, and bran flakes (p = .328).
Geometric mean of urinary excretion ratios for folic acid capsules, 3.68 at 24 hours and 2.18 at 48 hours, resulting from what appears to be two distinct clearance patterns for 13 C 6 and 2 H 4 , leave no doubt whatsoever that oral and IV isotopes of folic acid are handled differently, since ratios significantly greater that 1.0 are theoretically impossible if the isotopes were handled similarly by the body. This undermines the premise upon which the dual-label protocols are based. The recent commercial availability of an isotopically-labeled version of the [6S]-isomer of 5CH 3 H 4 PteGlu (natural isomer) should permit further dual-label studies to be undertaken with greater confidence.
Folic acid absorption from fortified foods
Although, in the current study, it can be concluded that 'absolute' absorption of oral dose cannot be calculated using urinary excretion ratios, the 'relative ratio' of test food UERs compared to folic acid capsule (control) UER may still be of some use. The 'relative ratio' approach would still retain the advantages of an increase in the precision of analysis while avoiding multi-blood sampling from volunteers. The 48 hour 13 C 6 / 2 H 4 urinary excretion ratio for white bread and bran flakes, when compared 'within-subject' to that for folic acid capsules, results in a geometric mean 'relative ratio' of 0.71 and 0.37, respectively, which suggests that the matrix of these cereal-foods has some inhibitory effect on intestinal absorption of folic acid added to the food as a fortificant. This supports earlier findings of relatively low folic acid absorption from fortified foods, as compared to folic acid alone, based on either short-term changes in plasma folate [19] , or longerterm studies measuring changes in erythrocyte folate concentrations [20] .
Relationship between urinary excretion of labeled folate and initial red blood cell folate (RBC) concentrations
Urinary excretion of 13 C 6 from folic acid capsules, but not white bread or bran flakes, was significantly correlated with the erythrocyte folate concentration of volunteers (r = 0.70, p = .004). RBC are known to correlate with liver folate stores, the major organ store in the body. Liver folate also correlates with whole body folate stores. It is suggested that the higher liver folate concentration, the lower the first pass absorption by the liver, and the higher urinary excretion of the dose. This is an area that needs further investigation.
Comparison of GC/MS and LC/MS procedures for determining labeled folate species
The GC/MS method used in this work is outlined in figure 1 . The procedure is very specific for folate and has a limit of detection of 0.25 ng/ml (0.11µM) of 5-MTHF in plasma. However, the method is tedious and is prone to both chemical and physical losses during sample preparation and derivatization. In particular, the cleavage reaction involving the conversion of 5-methyltetrahydrofolate to PABG using hydrogen peroxide and catalase is technically difficult to perform with low conversations often found (0 to 20%). In addition, the procedure requires a high resolution mass spectrometer, or a tandem instrument.
Alternate LC/MS and LC/MS/MS procedures have been developed [21] which require much simpler and rapid extraction and clean-up steps. A folate binding protein affinity column is used for sample clean-up, prior to determination by LC/MS or LC/MS/MS. The uptake of newly absorbed folate by the liver, resulting in the apparent limited short-term appearance in plasma of folate of oral origin, until recently has been seen as a limiting factor in the use of plasma kinetics in assessing absolute absorption [10] . However, the combination of this approach of using dual-label isotope protocols with 6S-5MTHF as the IV dose, with compartmental modeling techniques offer the potential for measuring absolute absorption of folates, and partitioning kinetics into other body pools.
Conclusions
Folic acid cannot be used as the IV dose in dual-label isotopic experiments. Where it has been used, even 'relative ratios' of test material UERs to a folic acid control UER should be viewed cautiously. In view of these findings, great care needs to be taken in the design of dual-label stable isotope protocols. We suggest that the only folate theoretically appropriate for IV use would be the natural isomer of 5-methyl-tetrahydrofolic acid ([6S]-5CH 3 H 4 PteGlu).
The matrix of some cereal-based foods may have an inhibitory effect on intestinal absorption of folic acid from some fortified foods, resulting in reduced bioavailability to levels that are similar to natural food sources. Recommendations to fortify all types of flour with folic acid may be inappropriate for wholemeal flours because of lower folate bioavailability from products made from these flours. Further consideration should be given to the type and formulation of breakfast cereals, used as vehicles for folic acid fortification, in order to maximize folate bioavailability.
The use of plasma responses suffers from the extensive first-pass hepatic uptake and enterohepatic recycling of newly absorbed folates from the oral dose but it is possible that the development and application of compartmental modeling techniques may be possible for determining absolute absorption and in vivo kinetics. The development of LC/MS and LC/MS/MS techniques offer advantages over the GC/MS approach both in terms of sample throughput (handling capacity) and improved precision. In addition, LC/MS offers the potential to quantify other reduced folate forms, that are important in metabolism, something that is difficult using the GC/MS approach because of the varying cleavage conditions for each folate.
